Achaogen, Inc. Company Profile

02:30 EDT 2nd August 2014 | BioPortfolio

Achaogen is a clinical-stage biopharmaceutical company focused on the discovery and development of antibiotics for the treatment of serious infections caused by multi-drug resistant, Gram-negative bacteria. The company’s pipeline includes ACHN-490, an aminoglycoside currently being evaluated in a Phase 2 clinical study for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis, and late-stage preclinical programs with demonstrated in vivo efficacy against Gram-negative pathogens of concern including P. aeruginosa and A. baumannii. Resistance to available antibacterial therapies continues to rise at an alarming rate and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today intended to combat tomorrow’s resistant pathogens. Achaogen has established specialized capabilities to pursue the discovery and development of new antibiotics, and has funded its growth with a blend of private investments and non-dilutive funding from partnerships with the NIH, the United States Department of Defense, and others. For more information, please visit the company’s website at

News Articles [23 Associated News Articles listed on BioPortfolio]

Achaogen raises $72 million in IPO

Infectious disease company Achaogen Inc. (NASDAQ:AKAO) jumped $2.30 (19%) to $14.30 on its first day of trading Wednesday after raising $72 million in an IPO through the sale of a bumped-up number of...

BioNotebook: Merck drops Ariad's ridaforolimus; United Therapeutics, Infinity, Verastem updates; Dipexium, Achaogen IPO terms

Ariad will regain ridaforolimus rights from Merck in November; United Therapeutics considers deals, protects patents; Infinity secures new debt; Verastem buys back VS-4718 rights; and Dipexium, Achaog...

IPO Preview: Achaogen

By IPOdesktop: Based in South San Francisco, CA, Achaogen (AKAO) scheduled a $65 million IPO on the Nasdaq with a market capitalization of $205 million at a price range midpoint of $13 for Wednesday,...

Achaogen, Dipexium set IPO terms

Infectious disease companies Achaogen Inc. (South San Francisco, Calif.) and Dipexium Pharmaceuticals LLC (White Plains, N.Y.) both set terms for their respective IPOs on NASDAQ. Achaogen plans to sel...

Achaogen completes IPO

Achaogen amends IPO

Achaogen financial update

Achaogen board of directors update

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

Achaogen, Inc.

Achaogen is a clinical-stage biopharmaceutical company focused on the discovery and development of antibiotics for the treatment of serious infections caused by multi-drug resista...


Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections.Â...

More Information about "Achaogen, Inc." on BioPortfolio

We have published hundreds of Achaogen, Inc. news stories on BioPortfolio along with dozens of Achaogen, Inc. Clinical Trials and PubMed Articles about Achaogen, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Achaogen, Inc. Companies in our database. You can also find out about relevant Achaogen, Inc. Drugs and Medications on this site too.

Search BioPortfolio:

Relevant Topic

Latest News Clinical Trials Research Drugs Reports Corporate
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks

Searches Linking to this Company Record